January, 2025

article thumbnail

NVIDIA champions Innophore partnership to model drug dynamics with AI

Pharmaceutical Technology

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

article thumbnail

Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease

PharmaTimes

Europes first biomarker trial seeks to prevent Crohns Disease onset

138
138
article thumbnail

Safety Risk Sinks Cargo Therapeutics’ Cancer Cell Therapy Prospect, Leading to 50% Staff Cut

MedCity News

Phase 2 data for Cargo Therapeutics CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025. The post Safety Risk Sinks Cargo Therapeutics Cancer Cell Therapy Prospect, Leading to 50% Staff Cut appeared first on MedCity News.

article thumbnail

HPLC method demonstrates value for quality control analysis of cardiovascular drug

European Pharmaceutical Review

Researchers have developed a high performance liquid chromatography (HPLC) method that enables accurate determination and precise impurity analysis of the adrenergic -receptor blocker Carvedilol. Carvedilol is commonly used drug to treat cardiovascular diseases , Yuan et al. explained. While there are a variety of methods that can detect and quantify carvedilol, these methods often have limitations in terms of sensitivity, selectivity, or the ability to simultaneously quantify carvedilol and its

article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Driving Biopharma Innovation and Operational Excellence in 2025

Pharma IQ

Discover how advancements in unified systems, patient diversity, and regulatory submissions will accelerate drug development & improve patient outcomes.

Biopharma 130
article thumbnail

PBMs have evaded lawmakers’ reform attempts so far. Could 2025 turn the tide?

PharmaVoice

How regulators could hit PBMs from multiple sides in the coming year.

130
130

More Trending

article thumbnail

Amgen’s lung cancer treatment gets conditional approval

PharmaTimes

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer

Patients 127
article thumbnail

Open Source Healthcare – The Cure for Stagnant Medical Innovation

MedCity News

We are living in a moment when many realize that collaboration yields better, faster and more affordable advances. Open source also enables the potential for bigger profits and revenue. Whats in reach: a small amount of money paid for treatments across millions of people, rather than expensive lifesaving treatments only for the few who can afford them.

article thumbnail

Streamlining mesenchymal stem cell (MSC) expansion

Pharmaceutical Technology

With increasing demand for cell and gene therapies, mesenchymal stem cells (MSCs) have gained attention for their versatility and potential.

119
119
article thumbnail

FDA issues first recommendations on AI for drug development

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has for the first time, issued draft guidance on using artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product. The guidelines address the safety, effectiveness or quality of these medicines. FDA has previously published a discussion paper that was produced to inform its guidance on AI in pharmaceutical drug development.

article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

4 companies to watch in the accelerating gene editing race

PharmaVoice

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

128
128
article thumbnail

CDC wants faster testing for bird flu in hospitals

pharmaphorum

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu, says CDC.

120
120
article thumbnail

AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025

PharmaTimes

Preclinical data highlights potential in treating Alzheimer's disease

112
112
article thumbnail

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

MedCity News

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The post Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

FDA approves Vertex’s acute pain treatment Journavx

Pharmaceutical Technology

The FDA has approved Vertex Pharmaceuticals oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

FDA 108
article thumbnail

Sustainability in Pharmaceutical Outsourcing

PharmaTech

Pharmaceutical Technology spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers.

article thumbnail

An ALS treatment wave is approaching, and this biotech CEO is ready to surf

PharmaVoice

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

112
112
article thumbnail

FDA issues first guidance on AI in medicine development

pharmaphorum

The FDA has placed the credibility of AI's 'context of use' in pharma development at the heart of its first guidance in this area

FDA 116
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

UK sees 70% increase in phase I advanced therapy clinical trials in 2024

PharmaTimes

Cell and Gene Therapy Catapult reveals significant growth in UK trials

111
111
article thumbnail

FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions

MedCity News

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.

FDA 134
article thumbnail

Purdue and Sackler family agree to $7.4bn national opioid settlement

Pharmaceutical Technology

The settlement ends the Sackler familys ownership of the Oxycontin developer Purdue Pharma.

Pharma 111
article thumbnail

Industry Outlook 2025: Through the Lens of a Service Provider

PharmaTech

Pharmaceutical Technology spoke with Adam Sherlock, CEO of Qinecsa, about the industry trends of 2024, the future technology agenda, and M&A prospects in 2025.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Merck is broadening its pipeline as Keytruda’s patent cliff looms

PharmaVoice

Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.

116
116
article thumbnail

UK kicks off £150m tender process for healthcare AI

pharmaphorum

The UK government has launched a 150 million procurement drive for artificial intelligence tools that can be used by the NHS.

article thumbnail

UK regulator warns against buying weight-loss medicines without prescription

PharmaTimes

MHRA urges caution over illegal medicines from beauty salons and social media

Medicine 114
article thumbnail

Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health

MedCity News

Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement. The post Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagships Valo Health appeared first on MedCity News.

Biopharma 125
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Sanofi reports Q4 2024 increase in net income to $916m

Pharmaceutical Technology

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching 880m ($833m).

105
105
article thumbnail

Goals of the Association for Prescription Psychedelics

Pharmaceutical Commerce

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), provides a peek into what the association has set out to accomplish.

article thumbnail

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

PharmaVoice

Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.

112
112
article thumbnail

Sun Pharma unit poised to buy Canadian biotech Antibe

pharmaphorum

Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation

Pharma 111
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.